Scientific Corner

Antonio Federico (AF): On January 29-30, there has been in Tubingen the Kick-Off Meeting of the EU Project Solve-RD. You and Prof. Olaf Riess are coordinating this project. Can you summarize the aim and the activities of this important project? Holm Graessner (HG): To obtain a molecularly confirmed diagnosis remains one of the largest challenges for rare disease patients. To jointly tackle this challenge a core group of four European Reference Networks including the European Reference Network for Rare Neurological Diseases has motivated, designed and put together the Solve-RD project which is the first ERN based H2020 funded research project. Solve-RD brings together 21 partners from 10 countries which will be running from 2018 to 2022.

It is our great pleasure to announce the 2nd edition of the EAN Task Force for Rare Neurologic Diseases Teaching Course, to be organized in Cluj-Napoca (Romania), from 5-7 September 2018. As last year’s event was a success, the Task… Continue Reading

In 2016, the EAN president Günther Deuschl and ECTRIMS (European Committee for Treatment and Research in MS) president Xavier Montalban have decided to join the forces of the two societies, and prepare a common guideline for the treatment of multiple sclerosis (MS). In view of the recent increase of medications approved for relapsing- and progressive MS, evidence-based guidance is needed to ensure standardized treatment of MS patients throughout Europe.

A new guideline on cerebral venous thrombosis (CVT) diagnosis and treatment issued by the European Stroke Organization (ESO) and endorsed by the European Academy of Neurology (EAN) was recently published in ESO (long version) and EAN (abbreviated version) official journals [1, 2].

It is a pleasure to share with the European neurological community the outcome of the first teaching course for rare neurological diseases. The course took place in Cluj-Napoca, Romania, from 7th to 9th September 2017.

Antonio Federico: What are the aims of your ERN? Helen Cross: The objectives of the EpiCARE network will be: To improve accessibility of detailed diagnostics to individuals of all ages with rare and complex epilepsies across Europe, including clinical evaluation and investigation.

ntonio Federico: What are the aims of your ERN? Teresinha Evangelista: Our MISSION: Through collaborative cross-border work the EURO-NMD ERN will improve the lives of EU citizens by improving diagnosis, treatment and the delivery of high-quality, accessible and cost-effective healthcare to patients with rare Neuromuscular Diseases (NMD) requiring a particular concentration of resources or expertise.

The EAN Rare neurological diseases task force will be holding its 1st teaching course under the auspices of Dafin F. Muresanu, Professor of Neurology at the “Iuliu Hatieganu” University of Medicine and Pharmacy, in Cluj-Napoca, Romania. This teaching course aims… Continue Reading

Establishment of European standards of diagnosis, treatment and care within the various subfields of neurology is one of the most important aims of the EAN. To reach this goal, EAN has set-up a Guideline Production Group (GPG), which provides scientific assistance to active Task Forces.

EAN has come a long way since the merge of EFNS and ENS and has since reorganised its Scientific Panels. There are currently 31 of them and their role is to co-ordinate clinical research at a European level; disseminate good… Continue Reading

Zika virus is an arbovirus, member of the family Flaviridae, genus Flavivirus, which has created an important public health emergency in the Americas after an epidemic outbreak associated with nervous system disorders.